CAJ | 학술논문

目的：观察辛伐他汀对COPD患者诱导痰炎性标志物、肺功能及临床症状的影响。方法82例慢性阻塞性肺疾病急性加重期(AECOPD)患者随机分为辛伐他汀干预组和常规治疗对照组各41例，干预组在常规治疗基础上加用辛伐他汀20 mg/d，观察两组于治疗前、治疗后1个月及6个月时诱导痰白细胞介素17(IL-17)、白细胞介素8(IL-8)及第1s用力呼气容积(FEV1)/用力肺活量(FVC％)、FEVl占预计值百分比(FEV1％)及COPD评估测试问卷(CAT)。结果干预组在1个月时IL-17、IL-8较对照组显著下降(P<0.05),但FEV1/FVC％、FEV1％及CAT差异无统计学意义(P>0.05)，6个月时IL-17、IL-8、FEV1/FVC％、FEVl％及 CAT均较对照组差异均有统计学意义(P<0.05)。结论辛伐他汀可以减轻COPD患者气道炎症反应，改善肺功能及临床症状。
목적：관찰신벌타정대COPD환자유도담염성표지물、폐공능급림상증상적영향。방법82례만성조새성폐질병급성가중기(AECOPD)환자수궤분위신벌타정간예조화상규치료대조조각41례，간예조재상규치료기출상가용신벌타정20 mg/d，관찰량조우치료전、치료후1개월급6개월시유도담백세포개소17(IL-17)、백세포개소8(IL-8)급제1s용력호기용적(FEV1)/용력폐활량(FVC％)、FEVl점예계치백분비(FEV1％)급COPD평고측시문권(CAT)。결과간예조재1개월시IL-17、IL-8교대조조현저하강(P<0.05),단FEV1/FVC％、FEV1％급CAT차이무통계학의의(P>0.05)，6개월시IL-17、IL-8、FEV1/FVC％、FEVl％급 CAT균교대조조차이균유통계학의의(P<0.05)。결론신벌타정가이감경COPD환자기도염증반응，개선폐공능급림상증상。
Objective To investigate the influence of Simvastatin on induced sputum inflammatory markers,pulmonary function and clinicallsymptom with chronic obstructive pulmonary diseases(COPD).Methods:82 patients with acute excerbation of COPD were randomly divided into the treatment group(41cases)and the controllgroup(41cases).The treatment group was treated with 20mg/d Simvastatin on the basis of the conventionalltherapy. The levels of induced sputum IL-17, IL-8,FEVl/FVC%,FEVl%,and CAT were observed before and 1 month and 6 months after the treatment.Results: 1 month after the treatment.there was statisticalldiference of induced sputum IL-17 and IL-8 between the two groups(P<0.05),but FEV1/FVC%,FEV1%%and CAT showed no statisticalldiference(P>0.05).6 months after the treatment induced sputum IL-17,IL-8,FEV1/FVC%,FEVl%and CAT were allbeter improved in the treatment group than in the controllgroup with significant diference(P<0.05).Conclusion: The application of Simvastatin can reduce airway inflammation of patients with COPD,relieve pulmonary function and cilinicallsymptom,which is worth clinicallpopularization and application.